EU Joint Clinical Assessment (JCA) has the potential to transform the evaluation of medicines in Europe, including orphan drugs. While there’s hope that JCAs will streamline fragmented processes and improve patient access, the road ahead is far from simple. Concerns... View More
Willingness to pay for new medicines has steadily declined in real terms in countries that incorporate cost-effectiveness thresholds in their pricing and reimbursement (P&R) processes. Nations such as the UK, Australia, Canada, and Sweden have not adjusted their thresholds for... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More
While gene therapies offer the potentially groundbreaking opportunity to improve outcomes for individuals with rare and severe diseases, their adoption introduces distinct challenges for health systems that are currently tailored for more conventional medicines. As such, there is a significant... View More
This ISPOR Europe panel explored the evolving landscape of CAR T therapies, their high potential for lifelong benefits, and the economic and logistical hurdles they face. From complex manufacturing to unique pricing and reimbursement challenges, CAR T therapies require novel... View More
On March 12th 2024, Richard Sear and Emilie Neez explored alternative pricing approaches for orphan medicines in a presentation at the World Evidence Pricing and Access Congress in Amsterdam. Supporting slides are available here; this companion piece provides our (the... View More
While the revision of the General Pharmaceutical Legislation (GPL) targets EU-level frameworks and processes, proposed changes are sure to have immediate as well as downstream consequences at the country level. This paper explores these potential consequences, focusing on a selection... View More